Literature DB >> 16814944

MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).

Aydanur Karg1, Zekiye Aydoğdu Dinç, Oktay Başok, Ahmet Uçvet.   

Abstract

There is a peptide sequence homology between the gene product of human MUC4 and rat Muc4/sialomucin complex (SMC). Each contains a transmembrane subunit with two epidermal growth factor (EGF)-like domains that act as ligand for ErbB2. MUC4 and ErbB2 mediate intracellular signaling pathways that are linked to repression of apoptosis and either to proliferation or to differentiation of tumor cells. This study investigates the expression of human MUC4 in neoplastic and corresponding non-neoplastic tissues, and the relation of MUC4 expression in neoplastic tissues to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in a series of 100 non-small cell lung carcinomas (NSCLCs). MUC4 and ErbB2 expressions and cell proliferation (PCNA) were shown using immunohistochemistry. Apoptotic index (AI) and tumor differentiation were determined by morphologic criteria. All the non-neoplastic bronchial tissues and 85% of NSCLCs showed MUC4 expression. MUC4 expression was found to be higher in neoplastic than in non-neoplastic tissues (Yates correction p: 0.0006). MUC4 expression was inversely correlated with AI (p=0.0002) and was correlated with ErbB2 expression (p=0.022), but not with PCNA counts and tumor stage. Our results indirectly suggest that MUC4, in association with ErbB-2, might be involved in the repression of apoptosis and differentiation rather than proliferation in tumor cells of NSCLCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814944     DOI: 10.1016/j.prp.2006.04.002

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  16 in total

1.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

2.  Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Authors:  Albert C Chen; Ilenia Migliaccio; Mothaffar Rimawi; Sara Lopez-Tarruella; Chad J Creighton; Suleiman Massarweh; Catherine Huang; Yen-Chao Wang; Surinder K Batra; M Carolina Gutierrez; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2012-05-29       Impact factor: 4.872

3.  Diversity of mucins in labial glands of infants.

Authors:  Mechthild Stoeckelhuber; Marco R Kesting; Denys J Loeffelbein; Christoph Schmitz; Klaus-Dietrich Wolff
Journal:  Histol Histopathol       Date:  2020-03-12       Impact factor: 2.303

4.  Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.

Authors:  Elisa Lappi-Blanco; Johanna M Mäkinen; Siri Lehtonen; Henna Karvonen; Raija Sormunen; Kirsi Laitakari; Shirley Johnson; Riitta Mäkitaro; Risto Bloigu; Riitta Kaarteenaho
Journal:  Tumour Biol       Date:  2016-08-01

5.  MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.

Authors:  Murielle Mimeault; Sonny L Johansson; Shantibhusan Senapati; Navneet Momi; Subhankar Chakraborty; Surinder K Batra
Journal:  Cancer Lett       Date:  2010-03-19       Impact factor: 8.679

6.  The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

Authors:  Heather C Workman; Colleen Sweeney; Kermit L Carraway
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 7.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 8.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

9.  Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press.

Authors:  Nicolas Jonckheere; Isabelle Van Seuningen
Journal:  Tumour Biol       Date:  2013-11-17

10.  The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.

Authors:  Heather C Workman; Jamie K Miller; Ellen Q Ingalla; Rouminder P Kaur; Diane I Yamamoto; Laurel A Beckett; Lawrence Jt Young; Robert D Cardiff; Alexander D Borowsky; Kermit L Carraway; Colleen Sweeney; Kermit L Carraway
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.